An observational study in Dementia Alzheimers, sponsored by University Medical Center Groningen. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-04.
Sponsored by University Medical Center Groningen · Observational
Rationale: A prominent and degenerative motor symptom of dementia is paratonia that heavily affects quality of life. However, paratonia is poorly recognized and the diagnosis yet relies on subjective evaluation by caregivers.
Objective: The primary aim of the proposed study is to develop a surface-electromyography-based method to objectively quantify paratonia in people with dementia. In addition, we aim to increase the understanding of the role of neuromuscular dysfunctions that contribute to paratonia.
Study design: Cross-sectional study, in people of various ages and at older age with different levels of cognitive impairment and neuromuscular functioning, in which we will examine the association between their physical and cognitive function and neuromuscular outcome measures.
Study population: Healthy young (18-30y, n = 40), middle-age (40-55y, n = 40) and older adults (>65y; n = 40). In addition, people with mild cognitive impairment (n = 40) as well as people with mild (n = 40), moderate (n = 40) and severe (n = 40) dementia.
Main study parameters/endpoints: Cognitive function, physical function, neuromuscular function expressed by muscle- and brain activity as well as coordination.
Nearly 300.000 people in the Netherlands and approximately 55 million people worldwide (WHO) suffer from dementia. With 60 - 70% of all cases, Alzheimer's disease (AD) is the most common form of dementia. While AD is mostly associated with cognitive dysfunction, motor symptoms - as acknowledged in DSM-5 - are part of the neurocognitive domain and have shown to precede cognitive decline in people with AD. These data highlight that dementia not only involves cognitive but also motor components. As such, objective screening tools that can detect these motor symptoms are critical yet unavailable.
A prominent and degenerative motor symptom related to AD is paratonia. Paratonia was first described almost two centuries ago and defined as increased muscle tone during passive movements that is proportional to the strength of the stimulus applied up to the production of counter-movements in the later stages of dementia. Paratonia, therefore, is a motor symptom of AD that heavily affects the quality of life and is often misunderstood and mistaken for behavior of a psychosocial nature. However, despite their impact, motor symptoms of AD receive surprisingly little attention. Indirect evidence suggests that paratonia results from central, i.e., frontal lobe disinhibition, as well as peripheral, i.e., impaired skeletal muscle function due to collagen cross-linking and intramuscular inflammation. Based on these data, it can be argued that paratonia can be objectively quantified using non-invasive electrophysiological measurements. Once developed, such accessible and low-cost screening tool provide evidence for the presence and severity of motor symptoms of dementia in clinical settings besides symptoms of cognitive decline.
Currently, the presence and severity of paratonia are assessed with, respectively, the subjective paratonia assessment instrument (PAI) and the subjective Modified Ashworth Scale for Paratonia (MAS-P). However, objective tools to examine paratonia in people with dementia are not available and as such, the diagnosis of paratonia relies solely on subjective interpretation of clinicians. In a recent review, our research group highlighted the various gaps of knowledge in paratonia-research related to the poor recognition of paratonia and the lack of clear guidance for health professionals. Because eExperimental evidence suggested the possibility to measure paratonia through muscle activity. ,This possibility arises from the hypothesis that the increased muscle tone results from lesions in the frontal cortex in people with dementia and consequently increased disinhibition of the motor cortex. In addition, it is also possible that the heightened muscle tone is (partly) caused by disturbed interactions between ascending sensory inputs and descending motor output. As such, it is reasonable to hypothesize paratonia can be objectively characterized by neurophysiological motor and corticomotor parameters. Moreover, there are indications that motor symptoms precede cognitive decline in people with dementia. Therefore, the goals of the proposed project are threefold and focus on (1) examining whether it is possible to the development of an objectively and non-invasively quantifyassessment the development of paratonia with a tool method based on surface electromyography (sEMG) to quantify paratonia, (2) examining the development of the relationship between motor symptoms of AD and cognitive and physical function from preclinical healthy adults to increasing severity of dementia and (3) identifying the contribution of underlying neuromuscular dysfunctions that are associated with the development of paratonia.
2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.
This study's planned enrollment of 280 is above the median of 250 across 482 observational studies indexed under Dementia.
Browse Dementia studies →University Medical Center Groningen is the lead sponsor of 609 studies on the registry; 174 are open to participants now.
Counted across the registry records on this site, refreshed daily.
We aim to include healthy young (18 - 30 y, n = 40), middle-aged (40 - 55 y, n = 40) and older adults (> 65 y; n = 40). In addition, we aim to include people with mild cognitive impairment (n = 40) as well as people with mild AD (n = 40), moderate AD (n = 40) and severe AD (n = 40). The severity of AD will be determined using the Clinical Dementia Rating.
In order to be eligible to participate in this study, healthy participants must meet all of the following criteria:
As for the people with AD, we will use the following inclusion criteria:
A potential healthy participant who meets any of the following criteria will be excluded from participation in this study:
A potential participant with dementia will be excluded from participation if:
Healthy young (18-30 years old) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
Behavioral: Elbow movement
Healthy middle aged (40-55y) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
Behavioral: Elbow movement
Healthy old (\>65y) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
Behavioral: Elbow movement
People with mild cognitive impairment (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
Behavioral: Elbow movement
People with mild dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
Behavioral: Elbow movement
People with moderate dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
Behavioral: Elbow movement
People with severe dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
Behavioral: Elbow movement
The behavioral paradigm consist of a passive and active movement condition. Both conditions consist of arm movements along the entire range of motion by moving the distal segment of the arm towards the proximal segment and back under varying conditions. In the 'passive' condition, this arm movement will be performed by researcher at 3 different velocities in sinusoidal (continuous) and linear (non-continuous) fashions whereas in the 'active' condition, the participant will be instructed to move the arm in one velocity under internal and external focus of attention.
Root mean square
From EMG data measured during flexion and extension movements, we will calculate the root mean square to assess the influence of movement velocity and shape as well as focus of attention on agonist and antagonist muscle activity.
Time frame: The measure 'root mean square' will be computed from electromyography data acquired during the session on Day 1 of the experiment.
Co-contraction index
From EMG data measured during flexion and extension movements, we will calculate the co-contraction index to assess the influence of movement velocity and shape as well as focus of attention on the control of agonist and antagonist muscle activity.
Time frame: The measure 'co-contraction index' will be computed from electromyography data acquired during the session on Day 1 of the experiment.
corticomuscular coherence
From EMG and EEG data measured during flexion and extension movements, we will calculate the corticomuscular coherence to assess the influence of movement velocity and shape as well as focus of attention on the connectivity between the brain and the muscles involved in the movement.
Time frame: The measure 'corticomuscular coherence' will be computed from electromyography and electroencephalography data acquired during the session on Day 1 of the experiment.
corticokinematic coherence
From goniometer and EEG data measured during flexion and extension movements, we will calculate the corticokinetic coherence to assess the influence of movement velocity and shape as well as focus of attention on the proprioceptive function during the involved movements.
Time frame: The measure 'corticokinematic coherence' will be computed from electroencephalography and goniometer data acquired during the session on Day 1 of the experiment.
cognitive function
As a measure of cognitive function, we will use the Montreal Cognitive Assessment.
Time frame: The measure 'cognitive function' will be estimated from the Montreal Cognitive Assessment taken on Day 1 of the experiment.
physical function
As a measure of physical function, we will use the Timed-Up and Go test and measure the time it takes (in seconds) to rise from a chair and walk three meters at comfortable speed, walk back and get seated again.
Time frame: The measure 'physical function' will be estimated from the Timed Up and Go test taken on Day 1 of the experiment.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen